Compare DRCT & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | PFSA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | 73 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 1.7M |
| IPO Year | 2021 | N/A |
| Metric | DRCT | PFSA |
|---|---|---|
| Price | $0.57 | $0.86 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 79.8K | ★ 6.5M |
| Earning Date | 05-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,694,000.00 | N/A |
| Revenue This Year | $58.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.05 |
| 52 Week High | $6.04 | $4.22 |
| Indicator | DRCT | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.44 | 49.33 |
| Support Level | $0.34 | $0.83 |
| Resistance Level | $0.61 | $2.22 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 12.54 | 23.59 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.